Celularity’s mission is to harness the power
of the living cell to augment biology,
immunity and longevity.
meet celularity
Celularity is a biotechnology company that productizes allogeneic cells and tissues derived from the postpartum placenta. These materials have the ability to augment our immunity and longevity by amplifying the body’s ability to fight disease, heal, and regenerate itself.
how it works
Celularity acts as a “biorefinery” to harness the power of the placenta to create therapies across autoimmune and degenerative diseases, immuno-oncology, and functional regeneration. The first company to own and deploy the full value chain from sourcing placental stem cells to patient treatment, Celularity is uniquely positioned to evolve and accelerate the field of cellular medicine.
cell therapy
Celularity is using stem cells derived from the placenta to create transformative therapeutic options for complex medical conditions from cancer to Crohn’s disease.
Celularity has over a dozen pre-clinical trials and Investigational New Drug applications (IND) in progress.
functional regeneration
Celularity has pioneered the use of placental biomaterials to create a suite of transplantable and implantable products, which support the body’s natural ability to restore tissue to a healthy state.
Celularity processes, distributes and markets BIOVANCE® and INTERFYL™ products, which are used by physicians to facilitate a patient’s regenerative process. Currently, both products are being utilized to treat a broad range of serious and complex wounds and burns, and is being employed in surgical, reconstructive and orthopedic applications.
Celularity is a leader in groundbreaking methods to produce whole organs and organoids from natural and bioprinted scaffolds which can be populated by Celularity’s placental stem cells as well as other progenitor cell types. Today, working with leading companies such as United Therapeutics, Celularity will bring Organ Regeneration to the market.
bio sourcing
Celularity offers the most comprehensive cord blood and placental blood and tissue biosourcing options available. This provides access to more of the stem cells needed for today’s treatments, and the potential to investigate tomorrow’s medical advancements.
Banking your child’s placental stem cells and tissue will provide them with an expanded range of options aimed at enhancing their health and longevity through future developments in regenerative medicine such as organ engineering.
Currently, stem cell transplants are accepted as standard therapy for more than 80 diseases. Some of these diseases—such as leukemia—are well known, but others are rare conditions for which there are limited treatment options.
why the placenta?
Celularity is the only company to use an allogenic placental platform. Because stem cells derived from the placenta are intrinsically safe, they can be taken from any placenta and injected into any human without the risk of rejection. These cells are also incredibly abundant, making treatments more affordable and immediate.
130M
BIRTHS PER YEAR
GLOBALLY
<.01%
OF PLACENTAS
ARE UTILIZED
|
1 PLACENTA |
= |
100K+ MEDICAL TREATMENTS |
big vision
AUGMENTED IMMUNITY
Celularity, through its strategic partner Sorrento Therapeutics, has acquired a powerful toolset to engineer cells for broad immunotherapeutic applications.
These include proprietary antibody and Chimeric Antigen Receptor (CAR) constructs that will allow Celularity to offer the world’s first immunotherapeutic suite of products against novel targets for cancer and immune disease. In addition, Celularity discovered a Natural Killer cell from the placenta and is actively developing therapeutic uses.
Celularity is developing the world’s first allogeneic off-the-shelf CAR-T cell receptor and CAR-NK products against a number of validated targets for immuno-oncology.
AUGMENTED LONGEVITY
Studies have shown as we age the population of stem cells resident in our organs and tissues declines exponentially, diminishing our body’s ability to heal and repair itself. Moreover, during our lifetime, our stem cells are damaged by environmental exposures rendering them less effective and adaptable.
By replenishing our reservoir of stem cells –– nature’s repair kit –– on an ongoing basis, we can augment our longevity.
Celularity seeks to make 100 years old the new 60, and to provide people with maximal aesthetics, mobility, and cognition as they age. We believe the 20 years of science, research, and intellectual property Celularity is built on is the cornerstone for the coming longevity revolution.
our pipeline
Celularity’s placental technology platform uses stem cells derived from the placenta to create therapeutic options for complex medical conditions ranging from cancer to Crohn’s disease. Celularity is the leader in cellular medicine with the deepest and broadest intellectual property portfolio of more than 800 issued patents.
our science
Read the latest publications relating to Celularity’s science.
our legacy
our founder
BOB HARIRI, MD, PhD
FOUNDER, CHAIRMAN & CEO
Dr. Robert (Bob) Hariri is the Founder, Chairman and CEO of Celularity.
He has worked for the past 20 years to transform the field of biomedicine where his discoveries and contributions to the study of stem cells and tissue engineering have sparked the development of nearly all existing stem cell therapies. In addition to Celularity, he is the Founder, and former Chairman and CEO of Celgene Cellular Therapeutics, a division of Celgene Corporation. He is also the Co-Founder and Vice Chairman of Human Longevity Inc.
LEADERSHIP TEAM
JOHN R. HAINES
EVP, CHIEF ADMINISTRATIVE OFFICER
LifebankUSA, Anthrogenesis
JEROME B. ZELDIS MD PHD
PRINCIPAL & CHIEF MEDICAL OFFICER
Celgene, Janssen
XIAOKUI ZHANG, PHD
EVP, CHIEF SCIENTIFIC OFFICER
Celgene, Rockefeller University
JODI GURNEY
EVP, CHIEF INNOVATION OFFICER
CCT, Celgene
TIMOTHY L. SMITH, JD PHD
EVP, GENERAL COUNSEL
Human Longevity, Novartis
STEVEN FRENCH
CHIEF INFORMATION OFFICER
Human Longevity, Epic Sciences
CURT QUIGLEY
SVP, CHIEF COMMERCIAL OFFICER
Celgene, Pfizer, Pharmacia
CARLOS RAMIREZ
SVP, INVESTOR & PUBLIC RELATIONS
JP Morgan, American Express
BILL WALLER
SVP, FINANCE & CONTROLLER
Celgene, Hearst
BETH STEINBRENNER
SVP, HUMAN RESOURCES
Celgene, Nabisco, Kraft Foods
BOARD OF DIRECTORS
PETER DIAMANDIS, MD
CO-FOUNDER & VICE CHAIRMAN
Dr. Peter Diamandis is the Founder & Executive Chairman of the XPRIZE and Executive Founder of Singularity University. He has Co-Founded 20 companies including Human Longevity Inc. Diamandis is the NY Times Bestselling author of Abundance & BOLD. He earned degrees in Molecular Genetics and Aerospace Engineering at MIT, and an M.D. from Harvard Medical School. Fortune Magazine recently named Diamandis as on of the World’s 50 Greatest Leaders.
JOHN SCULLEY
VICE CHAIRMAN
John Sculley is an American businessman and formerly Chief Executive Officer of Apple Inc and President of Pepsi-Cola. The companies John has advised cover many industries: health-tech (RxAdvance, Rally Health, MDLIVE, FLEXPharma, SleepMed); fin-tech (Lantern Credit); mobile-tech (MetroPCS); and marketing-tech (Zeta Interactive). Sculley received a bachelor’s degree in Architectural Design from Brown University and an MBA from the Wharton School of the University of Pennsylvania.
BILL MARIS
BOARD MEMBER
Founder, Section 32
ANDREW C. VON ESCHENBACH, MD
BOARD MEMBER
Former Commissioner, United States FDA
HENRI JI, PhD
BOARD MEMBER
Co-Founder & CEO, Sorrento Therapeutics
JAISIM SHAH
BOARD MEMBER
Chief Executive Officer, Senmur Pharmaceuticals
ANDREW PECORA, MD, FACP, CPE
BOARD MEMBER
Chief Innovation Officer, John Thereur Cancer Center
DAVID DEMING
BOARD MEMBER
Former Head, JPM Healthcare Investment Banking Group
STRATEGIC PARTNERS
INTERESTED IN LEARNING MORE ABOUT CELULARITY AND REGENERATIVE MEDICINE?
For media inquiries: media@celularity.com | For general inquiries: info@celularity.com